Yael Laitman1, Sarah M Nielsen2, Rinat Bernstein-Molho1,3,4, Brandie Heald2, Kathryn E Hatchell2, Edward D Esplin2, Eitan Friedman5,6,7. 1. The Oncogenetics Unit, Institute of Human Genetics, The Sheba Medical Center, Tel-Hashomer, Israel. 2. Invitae Corp, San Francisco, CA, USA. 3. The Breast Cancer Unit, Oncology Institute, The Sheba Medical Center, Tel-Hashomer, Israel. 4. The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 5. The Oncogenetics Unit, Institute of Human Genetics, The Sheba Medical Center, Tel-Hashomer, Israel. feitan@tauex.tau.ac.il. 6. The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. feitan@tauex.tau.ac.il. 7. Meirav High-Risk Clinic, Sheba Medical Center, 52621, Tel-Hashomer, Israel. feitan@tauex.tau.ac.il.
Abstract
PURPOSE: Cancer risks conferred by germline, heterozygous, ATM pathogenic/likely pathogenic variants (PSVs) are yet to be consistently determined. The current study assessed these risks by analysis of a large dataset of ATM heterozygote loss of function (LOF) and missense PSV carriers tested with a multigene panel (MGP). METHODS: De-identified data of all individuals who underwent ATM sequencing as part of MGP between October 2015 and February 2020 were reviewed. In cancer cases, rates for the six most prevalent variants and for all LOF and missense PSV combined were compared with rates of the same PSV in ethnically matched, healthy population controls. Statistical analysis included Chi-square tests and odds ratios calculations. RESULTS: For female breast cancer cases, LOF )1794/219,269) and missense (301/219,269) ATM PSVs were seen at higher rates compared to gnomAD non-cancer controls (n = 157/56,001 and n = 27/61,208; p < 0.00001, respectively). Notably, the rate of the c.103C > T variant was higher in controls than in breast cancer cases [p = 0.001; OR 0.31 (95% CI 0.1-0.6)]. For all cancer cases combined, compared with non-cancer population controls, LOF (n = 143) and missense (n = 15) PSVs reported in both datasets were significantly more prevalent in cancer cases [ORLOF 1.7 (95% 1.5-1.9) ORmissense 3.0 (95% CI 2.3-4); p = 0.0001]. CONCLUSION: Both LOF and missense heterozygous ATM PSVs are more frequently detected in cases of several cancer types (breast, ovarian, prostate, lung, pancreatic) compared with healthy population controls. However, not all ATM PSVs confer an increased cancer risk (e.g., breast).
PURPOSE: Cancer risks conferred by germline, heterozygous, ATM pathogenic/likely pathogenic variants (PSVs) are yet to be consistently determined. The current study assessed these risks by analysis of a large dataset of ATM heterozygote loss of function (LOF) and missense PSV carriers tested with a multigene panel (MGP). METHODS: De-identified data of all individuals who underwent ATM sequencing as part of MGP between October 2015 and February 2020 were reviewed. In cancer cases, rates for the six most prevalent variants and for all LOF and missense PSV combined were compared with rates of the same PSV in ethnically matched, healthy population controls. Statistical analysis included Chi-square tests and odds ratios calculations. RESULTS: For female breast cancer cases, LOF )1794/219,269) and missense (301/219,269) ATM PSVs were seen at higher rates compared to gnomAD non-cancer controls (n = 157/56,001 and n = 27/61,208; p < 0.00001, respectively). Notably, the rate of the c.103C > T variant was higher in controls than in breast cancer cases [p = 0.001; OR 0.31 (95% CI 0.1-0.6)]. For all cancer cases combined, compared with non-cancer population controls, LOF (n = 143) and missense (n = 15) PSVs reported in both datasets were significantly more prevalent in cancer cases [ORLOF 1.7 (95% 1.5-1.9) ORmissense 3.0 (95% CI 2.3-4); p = 0.0001]. CONCLUSION: Both LOF and missense heterozygous ATM PSVs are more frequently detected in cases of several cancer types (breast, ovarian, prostate, lung, pancreatic) compared with healthy population controls. However, not all ATM PSVs confer an increased cancer risk (e.g., breast).
Authors: Deborah Thompson; Silvia Duedal; Jennifer Kirner; Lesley McGuffog; James Last; Anne Reiman; Philip Byrd; Malcolm Taylor; Douglas F Easton Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: Hannes Helgason; Thorunn Rafnar; Halla S Olafsdottir; Jon G Jonasson; Asgeir Sigurdsson; Simon N Stacey; Adalbjorg Jonasdottir; Laufey Tryggvadottir; Kristin Alexiusdottir; Asgeir Haraldsson; Louise le Roux; Julius Gudmundsson; Hrefna Johannsdottir; Asmundur Oddsson; Arnaldur Gylfason; Olafur T Magnusson; Gisli Masson; Thorvaldur Jonsson; Halla Skuladottir; Daniel F Gudbjartsson; Unnur Thorsteinsdottir; Patrick Sulem; Kari Stefansson Journal: Nat Genet Date: 2015-06-22 Impact factor: 38.330
Authors: Chunling Hu; Steven N Hart; Rohan Gnanaolivu; Hongyan Huang; Kun Y Lee; Jie Na; Chi Gao; Jenna Lilyquist; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Josh Klebba; Christine B Ambrosone; Hoda Anton-Culver; Paul Auer; Elisa V Bandera; Leslie Bernstein; Kimberly A Bertrand; Elizabeth S Burnside; Brian D Carter; Heather Eliassen; Susan M Gapstur; Mia Gaudet; Christopher Haiman; James M Hodge; David J Hunter; Eric J Jacobs; Esther M John; Charles Kooperberg; Allison W Kurian; Loic Le Marchand; Sara Lindstroem; Tricia Lindstrom; Huiyan Ma; Susan Neuhausen; Polly A Newcomb; Katie M O'Brien; Janet E Olson; Irene M Ong; Tuya Pal; Julie R Palmer; Alpa V Patel; Sonya Reid; Lynn Rosenberg; Dale P Sandler; Christopher Scott; Rulla Tamimi; Jack A Taylor; Amy Trentham-Dietz; Celine M Vachon; Clarice Weinberg; Song Yao; Argyrios Ziogas; Jeffrey N Weitzel; David E Goldgar; Susan M Domchek; Katherine L Nathanson; Peter Kraft; Eric C Polley; Fergus J Couch Journal: N Engl J Med Date: 2021-01-20 Impact factor: 91.245
Authors: Kevin Spring; Farida Ahangari; Shaun P Scott; Paul Waring; David M Purdie; Philip C Chen; Kevin Hourigan; Jonathan Ramsay; Peter J McKinnon; Michael Swift; Martin F Lavin Journal: Nat Genet Date: 2002-08-26 Impact factor: 38.330
Authors: Mary B Daly; Tuya Pal; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Michael Goggins; Mollie L Hutton; Beth Y Karlan; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Holly J Pederson; Gwen Reiser; Leigha Senter-Jamieson; Kristen Mahoney Shannon; Rebecca Shatsky; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Matthew B Yurgelun; Susan D Darlow; Mary A Dwyer Journal: J Natl Compr Canc Netw Date: 2021-01-06 Impact factor: 11.908
Authors: David E Goldgar; Sue Healey; James G Dowty; Leonard Da Silva; Xiaoqing Chen; Amanda B Spurdle; Mary Beth Terry; Mary J Daly; Saundra M Buys; Melissa C Southey; Irene Andrulis; Esther M John; Kum Kum Khanna; John L Hopper; Peter J Oefner; Sunil Lakhani; Georgia Chenevix-Trench Journal: Breast Cancer Res Date: 2011-07-25 Impact factor: 6.466
Authors: Amin H Nassar; Sarah Abou Alaiwi; Saud H AlDubayan; Huma Q Rana; Guru Sonpavde; Nicholas Moore; Kent W Mouw; David J Kwiatkowski; Toni K Choueiri; Catherine Curran; Jacob E Berchuck; Lauren C Harshman; Pier V Nuzzo; Nieves Martinez Chanza; Eliezer Van Allen; Edward D Esplin; Shan Yang; Thomas Callis; Judy E Garber Journal: Genet Med Date: 2019-12-17 Impact factor: 8.822
Authors: N Jewel Samadder; Douglas Riegert-Johnson; Lisa Boardman; Deborah Rhodes; Myra Wick; Scott Okuno; Katie L Kunze; Michael Golafshar; Pedro L S Uson; Luke Mountjoy; Natalie Ertz-Archambault; Neej Patel; Eduardo A Rodriguez; Blanca Lizaola-Mayo; Michael Lehrer; Cameron S Thorpe; Nathan Y Yu; Edward D Esplin; Robert L Nussbaum; Richard R Sharp; Cindy Azevedo; Margaret Klint; Megan Hager; Sarah Macklin-Mantia; Alan H Bryce; Tanios S Bekaii-Saab; Aleksandar Sekulic; A Keith Stewart Journal: JAMA Oncol Date: 2021-02-01 Impact factor: 31.777